As reported, the tumor‐infiltrating macrophages led to anti‐PD‐1 resistance,[14] which is in line with our results, indicating the treatment prospects of combination therapy which include PI3Kγ inhibitors and anti‐PD‐1 in clinical patients after IRFA. The gene discussed is PDCD1; the disease is neoplasm.